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Abstract
Background: Hepatocellular carcinoma (HCC) is a common malignancy worldwide and
treatment options are depended on the stage of the tumour. In general, the prognosis of HCC
patients with extra-hepatic metastasis is poor. The most common sites of extra-hepatic metastasis
are the lung, abdominal lymph nodes and bone.
Case presentation: Here, we reported a 54-year-old man with an indolent clinical course of
HCC. He had multiple extra-hepatic recurrences after initial hepatectomy for HCC and was
benefited from repeated resections with prolonged survival. Eventually, he developed
intramuscular recurrence in the thigh, which was initially mistaken as deep vein thrombosis.
Conclusion: Selected patients with indolent disease course of HCC may benefit from repeated
resections of extra-hepatic metastases with prolonged survival.
Background
Hepatocellular carcinoma (HCC) is a common malig-
nancy worldwide, especially in Southeast Asia where viral
hepatitis is prevalent. Treatment options and thus progno-
sis are highly variable depending on the stage of the
tumor. The prognosis of HCC patients with extra-hepatic
metastasis is generally poor. The most common sites of
extra-hepatic metastasis are the lung, abdominal lymph
nodes and bone [1]. Rarely, HCC has been reported to
metastasize to the breast [2], pituitary gland [3], gingiva
and papillary muscle of the heart [4]. Intramuscular
metastasis from HCC is indeed very rare. Here, we
reported a 54-year-old patient with an indolent and inter-
esting clinical course of HCC.
Case presentation
A 54-year-man, who is a chronic hepatitis B carrier and
with Child A cirrhosis, presented with weight loss in 2002.
All along, he did not develop any variceal bleeding, ascites
or hepatic encephalopathy. Blood tests showed elevated
alpha-fetal protein (AFP) level of 458 ng/ml. Computer
tomography (CT) imaging of the abdomen confirmed a
7.5 × 7 × 7.7 cm lesion in segment IVb of the liver. He
underwent right tri-segmentectomy and at the time of sur-
gery his Model for End Liver Disease (MELD) score was
seven. Pathology showed a 8 × 5 × 4.5 cm HCC' with vas-
cular invasion. He was followed up regularly with serum
alpha-fetoprotein (AFP), chest x-ray and computed tom-
ography (CT) scan every three months. Nine months after
the initial operation, the disease recurred in the lung, with
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with lung secondaries. Video-assisted thoracoscopic
wedge resection of metastases in the right upper and lower
lobes was performed. Pathology confirmed metastatic
HCC in all resected lesions. However, six months after the
operation, he developed brain metastasis with magnetic
resonance imaging (MRI) of the brain showed a solitary
metastasis in the left occipital region. Whole brain irradi-
ation was offered, followed by craniotomy to resect the
residual tumor in 2004. Later, left upper lobectomy was
also performed for another intra-thoracic recurrence in
the same year. After these operations, he remained clini-
cally well with no clinical, serological and radiological
evidence of recurrence till early 2007. He presented with
progressive painful left thigh swelling for four months
and was initially suspected to have deep vein thrombosis.
Surprisingly, ultrasound study of the left thigh showed no
evidence of such, but abnormally enlarged left rectus fem-
oris with loss of normal muscle architecture. MRI sug-
gested the soft tissue mass was likely to be intramuscular
metastasis (Figure 1A–B). Ultrasound-guided biopsy
revealed fibromuscular tissue infiltrated by tumor cells,
which were immunohistochemically positive for HEPA
(Fig. 2A–B). The overall picture was compatible with infil-
tration by metastatic HCC. Simultaneously, he was found
to have a rise in AFP (177 ng/ml) and re-staging CT of the
thorax and abdomen revealed multiple secondaries in all
lobes of the lung. As a result, he was treated as widespread
metastatic HCC by single agent sorafenib. After its com-
mencement, the pain in left thigh had initially improved
but soon resistant to treatment. He developed progressive
disease with deteriorating condition and was finally suc-
cumbed of the disease in 2007.
Discussion
To our knowledge, there are only very few reports in the
literature regarding intramuscular HCC metastasis thus
far [5,6]. In fact, despite the rich vascular supply of the
muscle, it is rarely a site of metastasis in cancer patients
[7]. This interesting phenomenon may be due to the con-
tractility action of muscle, its local pH environment, and
accumulation of lactic acid and other metabolites in the
muscle [8].
The patient presented with a thigh metastasis. The other
differential diagnosis in this case is deep venous thrombo-
sis as HCC patients are found to have an increased risk for
thromboembolism [9]. However, deep vein thrombosis is
in fact a rare manifestation of hypercoagulable state in
HCC patients.
In the present case, the patient has an indolent disease
course of advanced HCC. His overall survival is largely
enhanced by aggressive multiple resections of all the
extra-hepatic sites of recurrence until finally the disease
became widespread with involvement of the rare site of
thigh muscle. In fact, in the literature, it is well recognized
that treatment for extra-hepatic recurrence is important in
prolonging survival especially in patients with well-con-
trolled primary [10]. However, there is no convincing evi-
A and B: Magnetic Resonance Images of left thighFigure 1
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metastases from primary HCC is beneficial to all patients
with metastatic HCC, albeit some studies suggested the
benefits of such approach in highly selected HCC patients
with distant metastases [11]. Nowadays, instead of aggres-
sive metastatectomy, a novel multi-targeted kinase inhib-
itor – sorafenib offers new hope to this group of patients
with unresectable metastases as it was shown to improve
the overall survival with tolerable toxicities [12].
Conclusion
Selected patients with indolent disease course of HCC
may benefit from repeated resections of extra-hepatic
metastases with prolonged survival. Eventually, the dis-
ease may develop recurrence in rare sites as illustrated in
the present case and cause dilemma in the diagnosis and
management.
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